Immunexpress

Immunexpress is a pioneer in host-response diagnostics for sepsis, a life-threatening condition that is the leading cause of death in hospitals. The company's core technology, SeptiCyte, quantifies specific gene expression markers from whole blood to rapidly identify sepsis, shifting the diagnostic paradigm from slow pathogen identification. Its commercial product, SeptiCyte RAPID, is a fully automated cartridge that runs on the Biocartis Idylla platform, providing results in one hour. The company aims to reduce sepsis mortality and the significant associated healthcare costs through early and accurate detection.

Host-response molecular diagnostics platform measuring mRNA gene expression from whole blood to detect the immune system's reaction to systemic infection.

Immunexpress competes in the sepsis diagnostics market against traditional methods like blood cultures and biomarkers like procalcitonin (PCT) and C-reactive protein (CRP), which are faster than cultures but less specific. It also faces emerging competition from rapid molecular pathogen detection panels (e.g., from BioFire, Luminex) and other host-response signatures under development. Its key differentiation is the FDA-cleared status of its specific host-response test and its one-hour turnaround time on an automated platform.